Using a candidate drug screen, the authors identified that inhibition of cyclin-dependent kinases 12 and 13 (CDK12/13) dramatically sensitized diverse models of TNBC to epidermal growth factor receptor (EGFR) blockade.
[Proceedings Of The National Academy Of Sciences Of The United States Of America]